Apologies, but no results were found. Perhaps searching will help find a related post.
Posted 7 January 2015: The Pharmaceutical Benefits Advisory Committee (PBAC) has approved both Sorafenib and Axitinib for treatment of stage IV (metastatic) clear cell variant renal cell carcinoma (RCC). These treatment options are for patients whose cancers have grown despite previous PBS-subsidised drug treatments (Sunitinib and Pazopanib). There are now five drugs available for Australians […]
Posted 1 December 2014: Kidney Health Australia provide resources and support for those affected by kidney cancer. Some of our established resources include a toll free phone and email information service, a dedicated website, an online community and a free Kidney Cancer Resource Pack which includes the Cancer Council’s Understanding Kidney Cancer booklet. Recently Kidney […]
Posted 24 November 2014: Results have been released from a phase II clinical trial testing the effectiveness of a combination of two existing anticancer drugs, bevacizumab and erlotinib, in treating advanced sporadic papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer (HLRCC). […]
Posted 8 October 2014: Kidney Health Australia recognises the need for further research into rare and less common cancers, including kidney cancer, and also the importance of kidney cancer patients having an active voice in rare cancer research. CART-WHEEL.org is an international, ethically approved website that collects information directly from people who are affected by […]
19 January 2015: The Union for International Cancer Control (UICC), in partnership with Cancer Council Australia hosted the World Cancer Congress in Melbourne in December at the Melbourne Convention and Exhibition Centre. The UICC is a global membership organisation to help the health community accelerate the fight against cancer. Their biennial Congress is a platform for […]